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Whilst many cases of greater trochanteric pain will settle with simple conservative 90 management options, a study based in primary care has shown that after one year 36% 91 of patients will still suffer with trochanteric pain, and at 5 years this remains 29% 92 indicating the chronic nature of this condition.
[1] Patients who received a 93 corticosteroid injection had a 2.7-fold chance of recovery compared to those who did 94 not.
[1] However one randomised controlled trial that sought to examine the benefits 95 of corticosteroid injection over usual care found a significant benefit favouring 96 injections at 3 months, but by 12months there was no benefit. [10] In addition to being 97 significantly more expensive, there appears to be no added clinical benefit in guided 98 versus unguided corticosteroid injections, with both often being effective in the short 99 and medium term, and 41%-47% patients still benefitting at three months. [11] Other 100 conservative treatment options that have been shown to be effective include 101 physiotherapy, non-steroidal anti-inflammatory drugs, and weight loss.
[4] Surgery has 102 been tried in recalcitrant cases and there have been a range of different techniques 103 reported with surgery focussing on the bursa, the tendinopathy, or the ITB 104 components of greater trochanteric pain syndrome, which highlights on-going 105 uncertainties as to the underlying pathologies in this condition. [12] [13] [14] 106 107 Extra-Corporeal Shockwave Therapy (ESWT) can also be used to treat patients with 108 trochanteric pain. This is the use of high-energy, inaudible, sound waves generated 109 externally to the body and which are transmitted through the skin, and are often felt as 110 vibrations. Whilst treatment doses vary, and there is case-control study showing 111 benefits of a single-dose of ESWT in patients with GTPS, [15] ESWT is most
The role of Extra-Corporeal Shockwave Therapy (ESWT) plus rehabilitation for patients with chronic Greater Trochanteric Pain Syndrome (GTPS), a case series assessing effects on pain, sleep quality, activity and functioning Page 6 typically performed over three sessions at weekly intervals in order to promote a 113 healing response alongside a structured rehabilitation programme. [3] This has a 114 growing evidence base in the treatment of a number of different tendinopathy 115 conditions, of which Greater Trochanteric Pain Syndrome may be one. Currently, 116
there is limited evidence of benefit from the use of Extra-corporeal Shockwave 117 Therapy (ESWT) specifically in patients with trochanteric pain, with the 2011 NICE 118 guidance (IPG 376) highlighting that overall the evidence was inconclusive. [16] 119
There is some case-series evidence which suggests benefit of ESWT [15] , and one 120 randomised control trial found that ESWT was better than physiotherapy or 121 corticosteroid injection at four-months, at fifteen-months there were similar results 122 from ESWT and physiotherapy, and that both were more effective than corticosteroid 123 injections alone.
[3] A subsequent systematic review looking at evidence in arrange of 124 lower-limb tendon conditions has suggested that ESWT may be useful in managing 125 patients with greater trochanteric pain syndrome as an alternative to other 126 conservative treatments such as corticosteroid injection. [17] The role of Extra-Corporeal Shockwave Therapy (ESWT) plus rehabilitation for patients with chronic Greater Trochanteric Pain Syndrome (GTPS), a case series assessing effects on pain, sleep quality, activity and functioning to promote adherence and facilitate progression. Patients are advised that these 168 exercises can be uncomfortable, particularly to begin with, and are taught how to 169 progress these. To support the use of the home exercise programme, patients are given 170 written sheets discussing these exercises and reminding them of technique and how 171 often these need to be performed for benefit. 172
The role of Extra-Corporeal Shockwave Therapy (ESWT) plus rehabilitation for patients with chronic Greater Trochanteric Pain Syndrome (GTPS), a case series assessing effects on pain, sleep quality, activity and functioning questionnaires are used to quantify levels of physical activity. These include the short-182 form (7-day recall) version of the International Physical Activity Questionnaire -183 IPAQ, and also two "vital signs" physical activity questions ("On how many days in 184 the last week have you been at least physically active?" and "on how many minutes 185 were you active for?" -multiplying these two figures together to give the number of 186 active minutes in a week.) 187
188
These measures are all used to examine outcomes following the ESWT procedure. 189 The role of Extra-Corporeal Shockwave Therapy (ESWT) plus rehabilitation for patients with chronic Greater Trochanteric Pain Syndrome (GTPS), a case series assessing effects on pain, sleep quality, activity and functioning
Page 11
Score ( The role of Extra-Corporeal Shockwave Therapy (ESWT) plus rehabilitation for patients with chronic Greater Trochanteric Pain Syndrome (GTPS), a case series assessing effects on pain, sleep quality, activity and functioning Page 12 193 194 Typically, patients are followed up three-months following ESWT, with a proportion 195 also seen at six-weeks where appointment availability allowed. Patients are then 196 routinely followed up after the three-month point if clinically required. the baseline data and data from the six-week, the three-month, and where data was 208 present the six-month follow-up appointments. As the sample sizes were small, the 209 Shapiro-Wilk test was used to assess normality and as the majority of the data was 210 found to be not normally distributed the majority of the analysis was performed with 211 non-parametric tests, typically the Wilcoxon Signed-Rank Test to look at pre/post 212 differences. 213
215
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Results
217
A total of 46 patients who underwent Extra-Corporeal Shockwave Therapy (ESWT) 218 for symptoms of trochanteric pain syndrome were identified from procedural logs. All 219 patients were treated with a Chattanooga Intelect RPW rESWT machine using the 220 withdrew from ESWT after their second session of treatment as she has been involved 231 in a road traffic collision (unconnected with her trochanteric pain or the ESWT 232 treatment) and was unable to attend the final treatment session due to her other 233 injuries. The data for this patient was therefore removed from analysis. 234
235
At least one set of follow-up results were available for all of the 45 patients that 236 completed ESWT. Normally patients are invited for follow-up at six-weeks, and 237 three-months following ESWT, and depending on symptoms also some are seen at 238 six-months. Not all patients attended for a six-week appointment post-ESWT due to 239 appointment scheduling and patient availability, with results available for 28/45
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patients (62%) at the six-week time point, and 44/45 (98%) at the three-month time-241 point, which is set as the primary outcome period. 242
243
Depending on the level on on-going symptoms at three-months, some patients also 244 had a six-month follow-up appointment booked, whereas others were left with an 245 open appointment for them to contact the department if there were problems or 246 questions. In total there were 27/45 responses from patients at six-months (60%), 247 however these figures may be skewed by the presence of on-going symptoms at three-248 months and may represent those with either poorer or slower outcomes. 249
250

 Patients 251
36 of the 45 patients (80%) who completed all three ESWT treatments for 252 trochanteric pain were female, and the majority of both male and female patients were 253 either overweight or obese. There was an average(SD) age of 60.9 (15.4) years, with 254 the youngest patient being 20 and the oldest being 86 years old. There was a mean 255 duration of symptoms of 43 months before trying ESWT, however this was skewed 256 by two patients having symptoms for ten years prior to ESWT, with the median 257 duration of symptoms being 30 months. 258 259 Before ESWT was conducted, all patients had been given a home exercise 265 programme; 91% had received formal physiotherapy input, the remainder had been 266 given exercises and exercise sheets from other consulting healthcare professionals. 267
There was a wide-range of treatment given prior to ESWT, with an average of 3.0 268 corticosteroid injections given by other healthcare professionals to patients prior to 269 referral for ESWT (range 0-8), with patients reporting an average of 3.6 weeks of 270 benefit from their most recent injection (range 0-20 weeks). One patient had 271 previously undergone surgery for their trochanteric symptoms one year prior to being 272 referred for ESWT. All patients had either received an MRI or an ultrasound scan to 273 examine the condition of the relevant muscles / tendons prior to ESWT as a part of 274 the consideration of treatment process. 275 276  Side-effects from ESWT 277
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The incidence of side-effects following ESWT is previously discussed and this was 278 investigated within this case series. Overall incidence of side-effects in this series is 279 low with 7% and 9% of patients reporting bruising at the 2 nd / 3 rd ESWT treatments 280 respectively, all of which had settled by the six-week and three-month follow-up 281 periods. No patient withdrew due to side-effects. The proportion of patients reporting themselves as pain free (VAS = 0) or virtually 290 pain-free (VAS of 0 or 1) at six-weeks was 7% and 11% respectively, at three-months 291 the figures were 9% and 18% respectively, and at six-months was 19% and 33% 292 respectively. 293
294
Overall there was an average reduction in pain as assessed by a 0-10 Visual Analogue 295 Scale (VAS) from 6.3 at baseline, to 4.1 at six-weeks, 3.8 at three-months, and 3.5 at
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six-months post-ESWT. These changes in pain from baseline were found to be 297 significant at all time-points at six or more weeks. This improvement correlates to an 298 average reduction of pain of about a third at all follow-up time points recorded. 299 300 Table 5 Table 5 : displaying baseline and follow-up pain and stiffness scores (all marked 307 on a 0-10 Visual Analogue Scale) 308
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These values are displayed in the Figure 1 The changes in "average pain", "worst pain" and "stiffness" were all significantly 315
improved from baseline at all of the follow-up appointments. Although a trend of 316 continued improvement appears to be shown in this series, for the "average pain" and 317 "average stiffness" the differences between the figures at six-weeks and subsequent 318 follow-ups did not reach statistical significance. For the "worst pain" there was a 319 statistically significant improvement in pain at 6-months compared to 6-weeks, but 320 not 3-months. These suggest that the majority of the benefits seen occur in the first 6-321 weeks after ESWT, although benefits appear to continue beyond this point. 322 323 324
 Sleep disturbance 325
Sleep disturbance is a commonly reported symptom from patients with trochanteric 326 pain syndrome, with pain sleeping on either the affected or the opposite side 327 commonly reported. Sleep quality was assessed by means of the Pittsburgh Sleep 328 Quality Index (PSQI), a patient self-reported questionnaire, at baseline and 329 subsequent follow-up appointments. This questionnaire rates a number of domains of 330 sleep quality and gives individual subs-scales as well as a global score which is 331 displayed here for simplicity, with a lower score indicating better sleep quality 332 overall.
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The following table displays the average (SD) global PSQI results obtained at 335 baseline and at follow-up. 336
Baseline 6-weeks 3-months 6-months PSQI (global) 10.9 (3.7) 9.7 (4.2) * 9.1 (3.7) * 9.0 (4.0) * Table 6 : displaying the global PSQI scores at baseline and at follow-up 337
338
The changes of global PSQI score from baseline to six-weeks, baseline to three-339 months and baseline to six-months, each of between 1.2 and 1.9 points, were all found 340 to be significant (p<0.05). However, the changes from six-weeks to either three or 341 six-months, and three-months to six-months, were not found to be significantly 342 The role of Extra-Corporeal Shockwave Therapy (ESWT) plus rehabilitation for patients with chronic Greater Trochanteric Pain Syndrome (GTPS), a case series assessing effects on pain, sleep quality, activity and functioning Many of the differences in scores from either baseline to six-weeks, baseline to three-356 months, or baseline to six-months showed a significant change (p<0.05) as indicated 357 above. The depression sub-scale of the Hospital Anxiety and Depression Scale 358 (HADS) was significantly improved following ESWT all time points, whereas the 359 anxiety sub-scale was only significantly different at the six-month follow-up time 360
point. The overall health% as recorded by the EQ-5D was only improved significantly 361 at six-weeks and six-months, but not at three-months, however the hip-specific 362 Patients with trochanteric pain syndrome often report that pain is a barrier to their 367 physical activity, therefore it may be assumed that if pain is reducing then physical 368 activity may increase. The measure this, the rates of physical activity were recorded 369 by using both the short form (7-day recall) International Physical Activity 370 Questionnaire (IPAQ) and also the "Vital signs" questions discussed previously. The only measures of physical activity that changed significantly from baseline was 375 decrease in the number of minutes of vigorous activity, and an increase in the number 376 of minutes of walking (both as assessed by the short-form IPAQ) measured at six-377 Overall levels of satisfaction with treatment was assessed on a 5-part Likert scale, 389 with 63% of patients being either "satisfied" or "very satisfied" at 3-months, and at 6-390 months this figure had increased to 75% In addition patients were asked if they would 391 recommend the ESWT treatment to a friend or family member with the same 392 symptoms on a four-part Likert scale. At 3-months 70% of patients would either
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